JPH07505375A - トレミフェンおよびその代謝物の局所投与 - Google Patents
トレミフェンおよびその代謝物の局所投与Info
- Publication number
- JPH07505375A JPH07505375A JP5517129A JP51712993A JPH07505375A JP H07505375 A JPH07505375 A JP H07505375A JP 5517129 A JP5517129 A JP 5517129A JP 51712993 A JP51712993 A JP 51712993A JP H07505375 A JPH07505375 A JP H07505375A
- Authority
- JP
- Japan
- Prior art keywords
- toremifene
- phenyl
- treatment
- pharmaceutically acceptable
- butene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims (12)
- 1.1つまたはそれ以上の薬学的に許容される賦形剤とともに、活性成分として トレミフェンまたはその代謝物のうちの1つであるN−デメチルトレミフェン( 4−クロロ−1,2−ジフェニル−[4−[2−(N−メチルアミノ)エトキシ ]フェニル]−1−ブテン)もしくは4−ヒドロキシトレミフェン(4−クロロ −1−(4−ヒドロキシフェニル)−2−フェニル−1−[4−[2−(N,N −ジメチルアミノ)エトキシ]フェニル]−1−ブテン)、またはそれらの薬学 的に許容される非毒性の塩からなる局所製剤。
- 2.軟膏、乳剤、ローション剤、水剤、ゲル剤またはクリーム剤の形態である請 求の範囲第1項記載の製剤。
- 3.製剤が経皮送達貼布システムである請求の範囲第1項記載の製剤。
- 4.活性成分がシクロデキストリンまたはシクロデキストリン誘導体の複合体の 形態である請求の範囲第2項または第3項記載の製剤。
- 5.活性成分がトレミフェンまたはその薬学的に許容される塩である請求の範囲 第1項〜第4項のいずれかに記載の製剤。
- 6.乳癌の治療に用いるための請求の範囲第1項〜第5項のいずれかに記載の局 所製剤。
- 7.乳癌の補助的な治療に用いるための請求の範囲第1項〜第5項のいずれかに 記載の局所製剤。
- 8.癌細胞の細胞毒性薬物に対する多剤耐性の反転に用いるための請求の範囲第 1項〜第5項のいずれかに記載の局所製剤。
- 9.黒色腫、リンパ腫、カポージ肉腫または菌状息肉腫の治療に用いるための請 求の範囲第1項〜第5項または第8項のいずれかに記載の局所製剤。
- 10.1つまたはそれ以上の薬学的に許容される賦形剤とともに、活性成分とし てトレミフェンまたはその代謝物のうちの1つであるN−デメチルトレミフエン (4−クロロ−1,2−ジフェニル−[4−[2−(N−メチルアミノ)エトキ シ]フェニル]−1−ブテン)もしくは4−ヒドロキシトレミフェン(4−クロ ロ−1−(4−ヒドロキシフェニル)−2−フェニル−1−[4−[2−一(N ,N−ジメチルアミノ)エトキシ〕フェニル]−1−ブテン)、またはそれらの 薬学的に許容される非毒性の塩からなる局所製剤の有効な量を、その治療が必要 な患者に局所投与することからなる乳癌の治療方法。
- 11.1つまたはそれ以上の薬学的に許容される賦形剤とともに、トレミフェン またはその代謝物のうちの1つであるN−デメチルトレミフェン(4−クロロ− 1,2−ジフェニル−[4−[2−(N−メチルアミノ)エトキシ]フェニル] −1−ブテン)もしくは4−ヒドロキシトレミフェン(4−クロロ−1−(4− ヒドロキシフェニル)−2−フェニル−1−[4−[2−(N,N−ジメチルア ミノ)エトキシ]フェニル]−1−ブテン)、またはそれらの薬学的に許容され る非毒性の塩を多剤耐性反転に有効な量をその治療が必要な患者に局所投与する ことからなる、細胞毒性薬物に対する癌細胞の多剤耐性を反転するための方法。
- 12.1つまたはそれ以上の薬学的に許容される賦形剤とともに、活性成分とし てトレミフェンまたはその代謝物のうちの1つであるN−デメチルトレミフェン (4−クロロ−1,2−ジフェニル−[4−[2−(N−メチルアミノ)エトキ シ]フェニル]−1−ブテン)もしくは4−ヒドロキシトレミフェン(4−クロ ロ−1−(4−ヒドロキシフェニル)−2−フェニル−1−[4−[2−(N, N−ジメチルアミノ)エトキシ]フェニル]−1−ブテン)、またはそれらの薬 学的に許容される非毒性の塩からなる局所製剤の有効な量をその治療が必要な患 者に局所投与することからなる、黒色腫、リンパ腫、カポージ肉腫または歯状息 肉腫の治療方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929207437A GB9207437D0 (en) | 1992-04-03 | 1992-04-03 | Topical administration of toremifene and its metabolites |
GB9207437.6 | 1992-04-03 | ||
PCT/FI1993/000119 WO1993019746A1 (en) | 1992-04-03 | 1993-03-25 | Topical administration of toremifene and its metabolites |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH07505375A true JPH07505375A (ja) | 1995-06-15 |
Family
ID=10713495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5517129A Ceased JPH07505375A (ja) | 1992-04-03 | 1993-03-25 | トレミフェンおよびその代謝物の局所投与 |
Country Status (20)
Country | Link |
---|---|
US (1) | US5605700A (ja) |
EP (1) | EP0633774B1 (ja) |
JP (1) | JPH07505375A (ja) |
AT (1) | ATE176757T1 (ja) |
AU (1) | AU674307B2 (ja) |
CA (1) | CA2133429C (ja) |
DE (1) | DE69323549T2 (ja) |
DK (1) | DK0633774T3 (ja) |
EE (1) | EE02972B1 (ja) |
ES (1) | ES2129515T3 (ja) |
FI (1) | FI944597A0 (ja) |
GB (1) | GB9207437D0 (ja) |
GR (1) | GR3029819T3 (ja) |
HU (1) | HU221813B1 (ja) |
IL (1) | IL104986A (ja) |
NO (1) | NO309225B1 (ja) |
NZ (2) | NZ249889A (ja) |
RU (1) | RU2140785C1 (ja) |
WO (1) | WO1993019746A1 (ja) |
ZA (1) | ZA931760B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003513903A (ja) * | 1999-11-08 | 2003-04-15 | ザ・ユニバーシティ・オブ・テネシー・リサーチ・コーポレーション | 前立腺癌の予防的化学療法 |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811447A (en) * | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
DE4311870C2 (de) * | 1993-04-10 | 1998-07-30 | Altramed Holdings Ltd | Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen |
CA2162586C (en) * | 1993-05-13 | 2006-01-03 | David J. Grainger | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
US6908910B2 (en) | 1993-08-06 | 2005-06-21 | The Children's Medical Center Corporation | Estrogenic compounds as anti-mitotic agents |
US5504074A (en) | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
GB9418067D0 (en) * | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
US20030083733A1 (en) * | 1997-10-10 | 2003-05-01 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5837313A (en) * | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US20020091433A1 (en) * | 1995-04-19 | 2002-07-11 | Ni Ding | Drug release coated stent |
US6099562A (en) * | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
GB9609171D0 (en) | 1996-05-02 | 1996-07-03 | Orion Yhtymae Oy | Antioxidant compounds |
US6764690B2 (en) * | 1996-05-29 | 2004-07-20 | Delsitech Oy | Dissolvable oxides for biological applications |
AU6959898A (en) * | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
US7846919B2 (en) * | 1998-02-10 | 2010-12-07 | Dermex Pharmaceuticals, Llc | Chelated 8-hydroxyquinoline and use thereof in a method of treating epithelial lesions |
US6248752B1 (en) * | 1998-02-27 | 2001-06-19 | Charles Duane Smith | Azabicyclooctane compositions and methods for enhancing chemotherapy |
US6632447B1 (en) * | 1998-05-07 | 2003-10-14 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
US6413535B1 (en) | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
US20040092602A1 (en) * | 1998-05-07 | 2004-05-13 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
US20030130316A1 (en) * | 2000-03-20 | 2003-07-10 | Steiner Mitchell S. | Method for chemoprevention of prostate cancer |
US20040186185A1 (en) * | 1998-05-07 | 2004-09-23 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
PL207462B1 (pl) * | 1998-05-07 | 2010-12-31 | Univ Tennessee Res Corp | Zastosowanie związku trifenyloalkenowego |
EP1124545B1 (en) * | 1998-08-11 | 2004-12-15 | EntreMed, Inc. | Use of 2-methoxyestradiol as anti-fungal agents |
FI982733A (fi) | 1998-12-17 | 2000-06-18 | Orion Yhtymae Oyj | Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia |
FI109332B (fi) * | 1998-12-17 | 2002-07-15 | Orion Yhtymae Oyj | Toremifeenin liukoisia koostumuksia |
CO5170459A1 (es) * | 1999-06-01 | 2002-06-27 | Pfizer Prod Inc | Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos |
US7087592B1 (en) | 1999-08-23 | 2006-08-08 | Entre Med, Inc. | Compositions comprising purified 2-methoxyestradiol and methods of producing same |
TW593256B (en) | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
US7135581B2 (en) | 2000-08-18 | 2006-11-14 | Entremed, Inc. | Antiangiogenic agents |
DE10042411A1 (de) * | 2000-08-30 | 2002-03-28 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System zur Abgabe von Exemestan |
CN1471400A (zh) * | 2000-10-06 | 2004-01-28 | ��������ҽѧ����˾ | 用于治疗***敏感性疾病的联合疗法 |
US6613083B2 (en) * | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
CN1679956A (zh) | 2001-11-29 | 2005-10-12 | Gtx公司 | 治疗因雄激素剥夺引起的症状 |
US20050080143A1 (en) * | 2001-11-29 | 2005-04-14 | Steiner Mitchell S. | Treatment of androgen-deprivation induced osteoporosis |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
JP3887588B2 (ja) * | 2002-08-30 | 2007-02-28 | 株式会社リガク | X線回折による応力測定法 |
US7371773B2 (en) * | 2003-02-04 | 2008-05-13 | Kabushiki Kaisha Yakult Honsha | Breast cancer resistance protein (BCRP) inhibitor |
US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
US8236861B2 (en) | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
CA2558014A1 (en) | 2004-03-12 | 2005-09-29 | Entremed, Inc. | Antiangiogenic agents |
MD2765G2 (ro) * | 2004-12-06 | 2006-01-31 | МЕРЕУЦЭ Ион | Unguent pentru tratamentul afectiunilor oncologice ale glandei mamare |
US20060270641A1 (en) * | 2005-05-31 | 2006-11-30 | Steiner Mitchell S | Method for chemoprevention of prostate cancer |
CA2646065C (en) | 2006-03-20 | 2014-01-14 | Entremed, Inc. | Disease modifying anti-arthritic activity of 2-methoxyestradiol |
AU2007252991B2 (en) | 2006-05-22 | 2012-08-02 | Hormos Medical Ltd. | Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis |
US20080176255A1 (en) * | 2007-01-23 | 2008-07-24 | Edward Sobek | Mold detection composition and methods |
ES2524002T3 (es) | 2007-02-14 | 2014-12-03 | Forendo Pharma Ltd. | Método para la preparación de derivados de trifenilbuteno con valor terapéutico |
WO2008099060A2 (en) | 2007-02-14 | 2008-08-21 | Hormos Medical Ltd | Methods for the preparation of fispemifene from ospemifene |
EP3202420B1 (en) * | 2008-12-11 | 2020-03-04 | Besins Healthcare Luxembourg SARL | Transdermal pharmaceutical compositions comprising a serm |
WO2011085303A1 (en) * | 2010-01-11 | 2011-07-14 | Gtx, Inc. | Method for hormone ablative therapy induced osteoporosis |
EP2563353B1 (en) * | 2010-04-30 | 2016-09-28 | University Of Rochester | Compounds for anti-fungal treatment |
JP6174156B2 (ja) | 2012-10-19 | 2017-08-02 | フェルミオン オサケ ユキチュア | オスペミフェンの製造方法 |
WO2014124504A1 (en) * | 2013-02-13 | 2014-08-21 | Katholieke Universiteit Leuven Ku Leuven Research & Development | Compositions and methods for treating biofilms |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58216129A (ja) * | 1982-05-27 | 1983-12-15 | オリオン―ユヒチュメ オサケ ユキチュア | 新規なアルカンおよびアルケン誘導体ならびにそれを有効成分とする医薬 |
JPS60130512A (ja) * | 1983-12-15 | 1985-07-12 | Nitto Electric Ind Co Ltd | 皮膚疾患治療用テ−プ製剤 |
JPS61500914A (ja) * | 1984-01-20 | 1986-05-08 | モベ−ジヤ−ビス,ピエ−ル | 経皮投与用抗エストロゲン薬剤 |
JPS63230641A (ja) * | 1987-03-19 | 1988-09-27 | Shiseido Co Ltd | 経皮吸収促進剤及びこれを含有する皮膚外用製剤 |
JPH029825A (ja) * | 1988-03-29 | 1990-01-12 | Univ Florida | 非経口投与用薬剤組成物 |
JPH03163015A (ja) * | 1989-08-23 | 1991-07-15 | Adrian L Harris | がん細胞の多剤耐性を消失させるための薬剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI77839C (fi) * | 1982-05-27 | 1989-05-10 | Farmos Oy | Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat. |
GB2126576B (en) * | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
GB8604528D0 (en) * | 1986-02-24 | 1986-04-03 | Ici Plc | Therapeutic agents |
DE3634016A1 (de) * | 1986-04-17 | 1987-10-29 | Lohmann Gmbh & Co Kg | Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung |
US5189212A (en) * | 1990-09-07 | 1993-02-23 | University Of Georgia Research Foundation, Inc. | Triarylethylene carboxylic acids with estrogenic activity |
-
1992
- 1992-04-03 GB GB929207437A patent/GB9207437D0/en active Pending
-
1993
- 1993-03-09 IL IL10498693A patent/IL104986A/xx not_active IP Right Cessation
- 1993-03-11 ZA ZA931760A patent/ZA931760B/xx unknown
- 1993-03-25 DE DE69323549T patent/DE69323549T2/de not_active Expired - Fee Related
- 1993-03-25 AU AU37544/93A patent/AU674307B2/en not_active Ceased
- 1993-03-25 JP JP5517129A patent/JPH07505375A/ja not_active Ceased
- 1993-03-25 WO PCT/FI1993/000119 patent/WO1993019746A1/en active IP Right Grant
- 1993-03-25 AT AT93906654T patent/ATE176757T1/de not_active IP Right Cessation
- 1993-03-25 CA CA002133429A patent/CA2133429C/en not_active Expired - Lifetime
- 1993-03-25 US US08/313,103 patent/US5605700A/en not_active Expired - Lifetime
- 1993-03-25 DK DK93906654T patent/DK0633774T3/da active
- 1993-03-25 ES ES93906654T patent/ES2129515T3/es not_active Expired - Lifetime
- 1993-03-25 RU RU94042727A patent/RU2140785C1/ru not_active IP Right Cessation
- 1993-03-25 NZ NZ249889A patent/NZ249889A/en unknown
- 1993-03-25 NZ NZ280219A patent/NZ280219A/en unknown
- 1993-03-25 HU HU9402830A patent/HU221813B1/hu not_active IP Right Cessation
- 1993-03-25 EP EP93906654A patent/EP0633774B1/en not_active Expired - Lifetime
-
1994
- 1994-09-30 NO NO943669A patent/NO309225B1/no unknown
- 1994-10-03 FI FI944597A patent/FI944597A0/fi not_active Application Discontinuation
- 1994-11-11 EE EE9400325A patent/EE02972B1/xx not_active IP Right Cessation
-
1999
- 1999-03-30 GR GR990400909T patent/GR3029819T3/el unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58216129A (ja) * | 1982-05-27 | 1983-12-15 | オリオン―ユヒチュメ オサケ ユキチュア | 新規なアルカンおよびアルケン誘導体ならびにそれを有効成分とする医薬 |
JPS60130512A (ja) * | 1983-12-15 | 1985-07-12 | Nitto Electric Ind Co Ltd | 皮膚疾患治療用テ−プ製剤 |
JPS61500914A (ja) * | 1984-01-20 | 1986-05-08 | モベ−ジヤ−ビス,ピエ−ル | 経皮投与用抗エストロゲン薬剤 |
JPS63230641A (ja) * | 1987-03-19 | 1988-09-27 | Shiseido Co Ltd | 経皮吸収促進剤及びこれを含有する皮膚外用製剤 |
JPH029825A (ja) * | 1988-03-29 | 1990-01-12 | Univ Florida | 非経口投与用薬剤組成物 |
JPH03163015A (ja) * | 1989-08-23 | 1991-07-15 | Adrian L Harris | がん細胞の多剤耐性を消失させるための薬剤 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003513903A (ja) * | 1999-11-08 | 2003-04-15 | ザ・ユニバーシティ・オブ・テネシー・リサーチ・コーポレーション | 前立腺癌の予防的化学療法 |
Also Published As
Publication number | Publication date |
---|---|
CA2133429C (en) | 2004-08-31 |
ES2129515T3 (es) | 1999-06-16 |
IL104986A0 (en) | 1993-07-08 |
FI944597A (fi) | 1994-10-03 |
AU674307B2 (en) | 1996-12-19 |
EE02972B1 (et) | 1997-04-15 |
NO309225B1 (no) | 2001-01-02 |
DE69323549T2 (de) | 1999-07-29 |
DE69323549D1 (de) | 1999-03-25 |
ZA931760B (en) | 1993-09-30 |
NZ280219A (en) | 1997-05-26 |
HU9402830D0 (en) | 1994-12-28 |
NO943669D0 (no) | 1994-09-30 |
US5605700A (en) | 1997-02-25 |
HU221813B1 (hu) | 2003-01-28 |
WO1993019746A1 (en) | 1993-10-14 |
DK0633774T3 (da) | 1999-09-20 |
RU2140785C1 (ru) | 1999-11-10 |
HUT70845A (en) | 1995-11-28 |
IL104986A (en) | 1997-08-14 |
CA2133429A1 (en) | 1993-10-14 |
GR3029819T3 (en) | 1999-06-30 |
NZ249889A (en) | 1996-02-27 |
ATE176757T1 (de) | 1999-03-15 |
AU3754493A (en) | 1993-11-08 |
GB9207437D0 (en) | 1992-05-20 |
EP0633774B1 (en) | 1999-02-17 |
NO943669L (no) | 1994-09-30 |
EP0633774A1 (en) | 1995-01-18 |
FI944597A0 (fi) | 1994-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07505375A (ja) | トレミフェンおよびその代謝物の局所投与 | |
EP3261646B1 (en) | Reduction of adipose tissue | |
US9220680B2 (en) | Compositions and methods for localized drug delivery through mammary papillae | |
EP0169214B1 (fr) | Medicament antioestrogene pour administration percutanee | |
US4826830A (en) | Topical application of glyciphosphoramide | |
US20120316246A1 (en) | Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy | |
JP2004515453A (ja) | 癌を化学療法および放射線療法に付する間に細胞を保護するための組成物および方法 | |
JP2007530498A (ja) | 4−ヒドロキシタモキシフェンの化学的に安定な組成物 | |
JP4938237B2 (ja) | 4−ヒドロキシタモキシフェンによる***痛の治療 | |
Pease et al. | Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand–foot syndrome: a newly recognized toxicity | |
JP2021508334A (ja) | 男性型禿頭症を含む皮膚障害を処置するための局所製剤 | |
US11318161B2 (en) | Methods of treating basal cell carcinoma and glioblastoma | |
US20130005824A1 (en) | Treatment of ischemic tissue | |
Soe et al. | Tissue distribution of transdermal toremifene | |
EP3801508A1 (en) | Treatments | |
JP2022065223A (ja) | 局所適用外用剤 | |
JP5072588B2 (ja) | 4−ヒドロキシタモキシフェンを用いた良性***疾患の治療および予防 | |
Bordoloi et al. | RECENT NANO TECHNOLOGICAL APPROACHES EMPHASIS ON LIPOSOMAL BASED NANO CARRIERS AND ITS FUTURE PROSPECTIVE IN TREATING SKIN CARCINOMA: A REVIEW | |
WO2021024150A1 (en) | Process for the preparation of anthraquinone topical formulation | |
Yawalkar et al. | Triphysol in Chronic Superficial Dermatomycoses | |
Li et al. | Transdermal delivery of letrozole: effects of vehicles and organic acids on its permeation through rat skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040810 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050809 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051027 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20051208 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20051027 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20051227 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20060425 |